Not a farm.
A machine.
Neural Acres builds sealed biological machines that cultivate pharmaceutical-grade Cordyceps militaris with autonomous climate control, continuous vision audits, and certifiable output governed by Kryleos Atmos-OS.
A Billion-Dollar Market
Running on Guesswork
The global Cordyceps militaris market was valued at USD 1.45B–1.8B in 2025, growing at a 9.7–11.09% CAGR — yet the entire supply chain remains fragile, inconsistent, and trapped in the 20th century.
Contamination Loss
Trichoderma mold and bacterial contamination wipe out entire batches. Traditional growers lose 30–50% of crops with zero early-warning systems.
Uncontrolled Potency
Cordycepin levels swing wildly — 2 mg/g to 15 mg/g — due to manual climate guesswork. Pharma buyers require ≥10 mg/g every batch.
Labor-Dependent & Fragile
Cultivation depends entirely on experienced operators. One absent technician can collapse an entire 60-day grow cycle.
No Compliance Data
Pharma and EU buyers demand GMP-traceable documentation. Traditional cultivation produces no audit trails — blocking premium markets entirely.
Kryleos Atmos-OS —
Biological Control Intelligence
The central nervous system of every Neural Acres facility. Not a timer. Not a thermostat. A continuously learning biological control intelligence that eliminates the parameter drift responsible for yield loss across the industry.
- ✓Precision microclimate governance across sealed grow zones
- ✓Computer vision reviews crop health and contamination risk
- ✓Phase 2 ML control expands from monitoring to full-system autonomy
- ✓Immutable compliance logs — GMP & ISO 22000 audit-ready
Built to Dominate
First-Mover in India
Zero automated Cordyceps facilities exist in India. Neural Acres establishes the category before competitors can replicate the IP.
Regulatory Moat
Immutable data logs + unidirectional facility flow fast-track GMP & ISO 22000 — a multi-year, multi-crore barrier for traditional competitors.
Proprietary Platform IP
Kryleos Atmos-OS is a reusable biological control platform. Future licensing to third-party growers creates a capital-light secondary revenue stream.
₹30–50 Lakhs
for 3.5–5.5% Equity
Phase 0 demo unit is under construction. Phase 1 commercial revenue begins Month 3. Angel investment bridges to CGTMSE collateral-free loan (₹50–60L).
INR 110.90L Phase 1 CapEx with annual revenue scenarios of INR 174.6L (conservative) to INR 232.8L (premium).